Abstract | PURPOSE: PATIENTS AND METHODS: BOPP was administered alone in increasing doses (0.25, 0.5, 1.0, 2.0, 4.0, or 8.0 mg/kg) preoperatively in patients with intracranial tumors undergoing postresection PDT until dose-limiting toxicity (DLT) was observed. RESULTS: Twenty-nine assessable patients with intracranial tumors received BOPP intravenously 24 hours before surgery. The recommended dose was 4 mg/kg. Dose escalation was limited by thrombocytopenia. The most common nonhematologic toxicity was skin photosensitivity. Pharmacokinetic parameters showed increased area under the plasma concentration-time curve and maximum concentration with increased dose. Tumor BOPP concentrations also increased with increased dose. CONCLUSION: BOPP at a dose of 4 mg/kg was well tolerated. DLT was thrombocytopenia, and photosensitivity was the only other toxicity of note. The efficacy of PDT using BOPP requires further exploration.
|
Authors | M A Rosenthal, B Kavar, J S Hill, D J Morgan, R L Nation, S S Stylli, R L Basser, S Uren, H Geldard, M D Green, S B Kahl, A H Kaye |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 19
Issue 2
Pg. 519-24
(Jan 15 2001)
ISSN: 0732-183X [Print] United States |
PMID | 11208846
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article)
|
Chemical References |
- Protoporphyrins
- Radiation-Sensitizing Agents
- boron protoporphyrin
|
Topics |
- Adult
- Aged
- Area Under Curve
- Brain Neoplasms
(drug therapy)
- Drug Administration Schedule
- Female
- Glioblastoma
(drug therapy)
- Humans
- Male
- Middle Aged
- Photochemotherapy
- Protoporphyrins
(pharmacokinetics, therapeutic use)
- Radiation-Sensitizing Agents
(pharmacokinetics, therapeutic use)
- Tissue Distribution
|